Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma Annika Wallin, PhDa, Malcolm Sue-Chu, PhDb, Leif Bjermer,

Slides:

Advertisements

Similar presentations

Assessment of inflammation in noninfectious chronic maxillary sinusitis Pascal Demoly, MDa, Louis Crampette, MDb, Michel Mondain, MDb, Alison M. Campbell,

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: A randomized, double-blind, parallel group.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Eosinophil cationic protein and histamine after intestinal challenge in patients with cow's milk intolerance Ulf Bengtsson, MD, PhDa, Tina W. Knutson,

Effect of montelukast for treatment of asthma in cigarette smokers

Hong Wei Chu, MDa, Monica Kraft, MDa, James E. Krause, PhDb, Michael D

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers Harold S. Nelson, MDa, Kenneth.

The effect of omalizumab on nasal allergic inflammation

Is 9 more than 2 also in allergic airway inflammation?

Youngil I. Koh, MD a, Inseon S

Badrul A. Chowdhury, MD, PhD

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma B.Lauren Charous, MD, Elkan F. Halpern,

Pathophysiology of severe asthma

Inflammation of small airways in asthma

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Elephantiasis nostras: A case report

Adverse effects of β-agonists

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

The impact of allergic rhinitis on bronchial asthma

Erythema multiforme to phenobarbital: Involvement of eosinophils and T cells expressing the skin homing receptor F.Jesus Gonzalez, PhDa, Maria J. Carvajal,

IL-11 expression is increased in severe asthma: Association with epithelial cells and eosinophils Eleanor Minshall, PhDa, Jamila Chakir, PhDb, Michel.

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Expression of IFN-γ–inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases Deborah Miotto,

A review of the current guidelines for allergic rhinitis and asthma

Evidence for expression of eosinophil-associated IL-12 messenger RNA and immunoreactivity in bronchial asthma Esra Nutku, MDa, Abdelilah Soussi Gounni,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Physician-targeted program on inhaled therapy for childhood asthma

News & Notes Journal of Allergy and Clinical Immunology

The immunopharmacology of mild asthma

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Circadian variation of sputum inflammatory cells in mild asthma

The Management of Eosinophilic Esophagitis

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: A randomized, double-blind, parallel group.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Molecular virology and immunology of HIV infection

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

News & Notes Journal of Allergy and Clinical Immunology

Corticosteroid-induced apoptosis in mouse airway epithelium: Effect in normal airways and after allergen-induced airway inflammation Delbert R. Dorscheid,

No correlation between wine intolerance and histamine content of wine

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma Yasurou Kohno, MDa,

Assessment of inflammation in noninfectious chronic maxillary sinusitis Pascal Demoly, MDa, Louis Crampette, MDb, Michel Mondain, MDb, Alison M. Campbell,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis Lennart Greiff, MD, PhDa, Carl G.A. Persson,

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,

Delayed eosinophil apoptosis in asthma

Seasonal intestinal inflammation in patients with birch pollen allergy

Allergy and asthma in elite summer sport athletes

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway.

Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure Susan Colilla, PhDa*, Dan Nicolae, PhDb, Anna Pluzhnikov,

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy Diane J. Pincus, MD, Teresa R. Humeston,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: A 5-year prospective follow-up.

Cytokine profile in minor salivary glands from patients with bronchial asthma Anne Tsicopoulos, MDa, b, Anne Janin, MDc, Hikmat Akoum, PhDa, Catherine.

National trends in asthma visits and asthma pharmacotherapy,

Prescott G. Woodruff, MD, MPH, Ramin Khashayar, MD, Stephen C

Larry C. Borish, MDa, Harold S

Andrea J. Apter, MD, MSca, c, Susan T

Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

News & Notes Journal of Allergy and Clinical Immunology

Primary prevention of asthma and allergy

Presentation transcript:

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma Annika Wallin, PhDa, Malcolm Sue-Chu, PhDb, Leif Bjermer, MDc, Jonathan Ward, BScd, Thomas Sandström, MD, PhDa, Anne Lindberg, MDe, Bo Lundbäck, MD, PhDef, Ratko Djukanovic ́, DMd, Stephen Holgate, DScd, Susan Wilson, PhDd Journal of Allergy and Clinical Immunology Volume 112, Issue 1, Pages 72-78 (July 2003) DOI: 10.1067/mai.2003.1518 Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 1 Flow diagram indicating the total number of subjects randomized and the study inclusion criteria. The clinical characteristics for each treatment are summarized; the withdrawals within each group and total number of completed subjects are also given. All data are mean (± SE). *P < .05 compared with FP 400. Journal of Allergy and Clinical Immunology 2003 112, 72-78DOI: (10.1067/mai.2003.1518) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 2 Graphs of clinical data depicting (A) FEV1, (B) morning PEF, and (C) evening PEF before and after each treatment. Significant differences are indicated. Journal of Allergy and Clinical Immunology 2003 112, 72-78DOI: (10.1067/mai.2003.1518) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 3 Graph showing the number of (A) mast cells and (B) eosinophils in the submucosa. Significant changes are shown. These were the primary study end points. Journal of Allergy and Clinical Immunology 2003 112, 72-78DOI: (10.1067/mai.2003.1518) Copyright © 2003 Mosby, Inc. Terms and Conditions